A mAb for the detection of the antiretroviral drug emtricitabine

0Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Antibody-based testing for emtricitabine (FTC), a critical component of pre-exposure prophylaxis and antiretroviral therapy, would provide low-cost detection for clinical monitoring to improve adherence. We developed a mAb (5D2) to FTC and demonstrated its high specificity and physiologically relevant linear range of detection in a competitive enzyme immunoassay. Thus, this mAb is a key reagent that will enable simple and low-cost lateral flow assays and enzyme immunoassays for adherence monitoring.

Cite

CITATION STYLE

APA

Youngpairoj, A. S., Vanderford, T. H., Reed, M. S., Granade, T. C., Pau, C. P., Pohl, J., … Heneine, W. (2022). A mAb for the detection of the antiretroviral drug emtricitabine. AIDS, 36(13), 1890–1893. https://doi.org/10.1097/QAD.0000000000003357

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free